Hemostasis in COVID-19
DOI:
https://doi.org/10.37051/mir-00062Keywords:
SARS-CoV-2, COVID-19, Pulmonary embolism, Thromboprophylaxis, ThrombosisAbstract
Patients with severe COVID-19 pneumonia are at high risk of thrombotic complications related to coagulopathy induced by CoV-2-SARS, which worsens their prognosis. The pathophysiological mechanisms of this coagulopathy include endothelial dysfunction partly explained by a hyperinflammatory state and the resulting activation of coagulation. Current methods for assessing hemostasis do not seem to be enough to evaluate this thrombotic over-risk and the thromboprophylaxis goals probably needs to be increased.
Downloads
Published
2021-06-16
How to Cite
Merdji, H., Sattler, L., Cunat, S., Meziani, F., & Helms, J. (2021). Hemostasis in COVID-19. Médecine Intensive Réanimation, 30(Hors-série 1), 35–42. https://doi.org/10.37051/mir-00062
Issue
Section
Update